Quick answer: In a Phase 1b study of LY3437943 (retatrutide) in adults with type 2 diabetes, the reported elimination half-life was approximately six days. That is a study-level pharmacokinetic estimate under a defined protocol. It does not say how long an individual will experience an effect, establish a personal clearance timeline, or verify an online product.
Searches such as “retatrutide half life” often flatten pharmacokinetics into one number. This guide traces that number to published research, explains what half-life means, and separates plasma elimination from clinical effect and material stability.
What retatrutide half-life has been reported?
The Phase 1b multiple-ascending-dose trial of LY3437943 in adults with type 2 diabetes reported a half-life of approximately six days and dose-proportional pharmacokinetics. The study was published in The Lancet Diabetes & Endocrinology in 2022. A later Phase 2 publication also describes the approximate six-day value while discussing the drug candidate’s pharmacokinetic profile.
The estimate belongs to those study conditions and the analyzed participants. It is not a universal clock for everyone, and a value reported in a clinical trial cannot be applied to an unverified research product. The study involved a defined investigational drug, protocol, sampling schedule, and analytical method.
What does elimination half-life mean?
Elimination half-life is the time associated with a reduction of a measured concentration by half during the terminal elimination phase, as described by the pharmacokinetic model and sampling data. It is a summary statistic for drug concentration over time; it is not a direct measure of receptor activity, symptom duration, or a guaranteed time until a substance is absent.
Why the word “terminal” matters
After a drug enters the body, measured concentrations can reflect more than elimination alone. Absorption from the administration site, distribution between tissues and plasma, protein binding, metabolism, and measurement limits may affect the observed concentration curve. Researchers identify a terminal phase from serial measurements and apply a defined analysis.
Half-life is not the same as effect duration
A pharmacodynamic response can rise or fall on a different timeline from plasma concentration. The response may depend on receptor engagement, downstream biology, study endpoint, and the individual. Therefore, “approximately six days” should be described as the reported pharmacokinetic half-life, not as a promise about how long an effect lasts.
How do researchers estimate half-life?
In a pharmacokinetic study, investigators collect timed biological samples under a protocol, quantify the investigational molecule with a validated method, and analyze concentration-time data. The terminal half-life is calculated from the terminal slope using the study’s analysis plan. The estimate depends on adequate sampling during the terminal phase and reliable quantification.
Study details that help interpret the estimate
- Population: participant characteristics and inclusion criteria.
- Design: single- or multiple-dose schedule, comparison groups, and study duration.
- Sampling: collection times, length of follow-up, and how concentrations below quantification are handled.
- Analysis: model, terminal-phase selection, variability, and reported uncertainty.
- Assay: the analytical method used to measure retatrutide concentrations.
These details matter more than repeating a lone number without its source. If a paper reports a mean, range, or model-derived estimate, retain that exact qualifier rather than implying greater precision.
How is half-life different from stability?
Half-life in a person describes a pharmacokinetic estimate for a drug in a biological system. Stability describes whether a material retains specified properties under tested storage and handling conditions. They answer different questions and use different study designs.
A six-day human half-life does not mean a vial remains stable for six days, nor does a seller’s storage claim establish the molecule’s pharmacokinetics. Conversely, a stable laboratory reference does not prove a clinical half-life. Avoid transferring a number from one context to the other.
What the six-day estimate cannot tell you
The published Phase 1b estimate does not establish an individual’s concentration curve, safety, clinical response, or a product’s identity. Retatrutide remains investigational and is not FDA-approved. Research papers describe the investigational material used under study oversight; they do not validate separate products marketed online.
This article is research education only. It does not provide dosing, timing, discontinuation, preparation, injection, treatment, or sourcing instructions. For study-specific interpretation, read the paper and its supplement; for current regulatory status, consult official FDA information and trial registries.
Retatrutide half-life FAQs
What is the reported half-life of retatrutide?
A Phase 1b trial reported an approximate half-life of six days for LY3437943. Treat it as an estimate from that study, not an individual prediction.
Does a six-day half-life mean retatrutide is gone after six days?
No. Half-life describes a proportional change in measured concentration during a defined elimination phase. It is not a binary present-or-absent threshold.
Is half-life the same as how long a product remains stable?
No. Pharmacokinetic elimination in people and chemical or physical stability under storage conditions are separate properties.
Does the reported value apply to every product labeled retatrutide?
No. The study result concerns its investigational material and protocol. A label alone does not demonstrate that another material is identical.
References
- Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet Diabetes & Endocrinology. 2022;10(9):646–656. doi:10.1016/S2213-8587(22)00233-5.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial. New England Journal of Medicine. 2023;389:514–526. doi:10.1056/NEJMoa2301972.
- FDA. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Accessed October 10, 2026.
Editorial note: This summary describes published pharmacokinetic research and is not medical advice. It does not estimate an individual’s response or provide use instructions. Reviewed October 10, 2026.
